Alto Neuroscience (ANRO) Accounts Payables (2023 - 2026)

Alto Neuroscience has reported Accounts Payables for 4 years, with the latest figure at $3.4 million in Q1 2026.

• Quarterly Accounts Payables rose 143.42% year-over-year to $3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 million (up 143.42% YoY) and the FY2025 annual result came in at $1.9 million, up 18.94% from the prior year.
• Accounts Payables rose to $3.4 million in Q1 2026 per ANRO's latest filing, from $1.9 million in the prior quarter.
• Over five years, Accounts Payables peaked at $3.4 million in Q1 2026 and troughed at $1.1 million in Q4 2023.
• A 4-year average of $2.0 million and a median of $1.9 million in 2024 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2025 and 2026: Accounts Payables plunged 42.62% in 2025, then surged 143.42% in 2026.
• Over 4 years, Accounts Payables stood at $1.1 million in 2023, then jumped by 47.02% to $1.6 million in 2024, then advanced by 18.94% to $1.9 million in 2025, then surged by 79.39% to $3.4 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $3.4 million, $1.9 million, and $2.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.